Orforglipron vs Cagrilintide.

Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.

Cagrilintide (development code AM833) is a long-acting, once-weekly synthetic analogue of the pancreatic hormone amylin, developed by Novo Nordisk. It is a "dual amylin and calcitonin receptor agonist" (DACRA)-class peptide engineered with a lipidation (fatty-acid acylation) that prolongs its half-life, and is being investigated for chronic weight management in adults with overweight or obesity, both as a monotherapy and as the amylin component of the fixed-dose combination CagriSema (with semaglutide).

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

Native amylin is co-secreted with insulin from pancreatic beta cells and reduces food intake by promoting meal-ending satiety, slowing gastric emptying, and suppressing glucagon. Cagrilintide mimics this by activating amylin and calcitonin receptors, which are heterodimers of the calcitonin receptor with receptor-activity-modifying proteins (RAMPs). Preclinical work in RAMP1/RAMP3 knockout mice (eBioMedicine, 2025) indicates cagrilintide's weight-lowering effect is mediated largely through brain amylin receptors 1 and 3 in hindbrain and hypothalamic circuits that govern appetite. Because amylin signaling is mechanistically distinct from GLP-1, combining the two (as in CagriSema) is intended to engage complementary satiety pathways and produce additive weight loss.

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

Human data are now substantial for the combination and growing for monotherapy. The pivotal phase 3 REDEFINE 1 trial in over 3,400 adults with overweight/obesity without diabetes (NEJM 2025, PMID 40544433) reported mean weight loss of roughly 20.4% with CagriSema, 11.8% with cagrilintide monotherapy, 14.9% with semaglutide, and about 3% with placebo at 68 weeks; cagrilintide thus produced clinically meaningful weight loss on its own, though less than the combination. REDEFINE 2 studied CagriSema in type 2 diabetes, and additional REDEFINE/REIMAGINE program trials (e.g., REIMAGINE 2 in The Lancet Diabetes & Endocrinology, 2026) extend the dataset. The brain-receptor mechanism evidence (eBioMedicine, PMID 40609154) is preclinical (mouse), so the molecular target attribution should not be read as proven in humans; most large efficacy data describe the semaglutide combination rather than cagrilintide alone.

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

In the REDEFINE program the safety profile of cagrilintide and CagriSema was reported as broadly consistent with incretin/amylin-based therapies, with predominantly mild-to-moderate gastrointestinal effects (nausea, vomiting, diarrhea, constipation) as the most common adverse events, generally most pronounced during dose escalation. Long-term safety, cardiovascular outcomes, and the safety of cagrilintide as a standalone therapy are not yet fully characterized in published phase 3 data, and head-to-head long-term comparisons remain limited. As an investigational agent, cagrilintide has no established safety profile for use outside of controlled clinical trials; material sold as research-only "cagrilintide" is not a regulated medicine and carries unknown identity, purity, and contamination risks.

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

Cagrilintide is investigational and not approved by the FDA as a standalone drug. Novo Nordisk submitted an NDA for the CagriSema combination (cagrilintide plus semaglutide) for weight management on December 18, 2025; as of mid-2026 it remains under FDA review and is not yet approved.